Lupin Limited

Last updated

Lupin Limited
Type Public
BSE:  500257
NSE:  LUPIN
Industry Pharmaceuticals
Founded1968;55 years ago (1968) [1]
Founder Desh Bandhu Gupta [2]
Headquarters
Mumbai, Maharashtra [3]
,
India
Key people
 Vinita D. Gupta (CEO) [4]
Nilesh Gupta (MD) [5] [6]
Products Pharmaceuticals, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health
RevenueIncrease2.svg₹16,715 crore (US$2.1 billion) [7]  (2023)
Increase2.svg₹716 crore (US$90 million) [7]  (2023)
Increase2.svg₹447 crore (US$56 million) [7]  (2023)
Total assets Increase2.svg₹22,955 crore (US$2.9 billion) [7]  (2023)
Total equity Increase2.svg₹12,464 crore (US$1.6 billion) [7]  (2023)
Number of employees
18,686 (2021)
Website www.lupin.com
Footnotes /references
[8]

Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally. [9] The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

Contents

History and evolution

Lupin was founded in 1968 by Desh Bandhu Gupta, [10] who was a professor of chemistry at BITS-Pilani, Rajasthan. Gupta initially borrowed Rs. 5000 from his wife to fund the venture. Due to subsequent funding from the Central Bank of India, the company able to start their manufacturing facility for producing folic acid and iron tablets for the Indian government's mother and child health program. Later Lupin started manufacturing anti-tuberculosis (TB) drugs which at one point formed 36% of the company sales and was considered as the largest TB drugs manufacturer in the world. [11]

In 1988 Gupta founded the group's CSR arm, the Lupin Human Welfare & Research Foundation (LHWRF). This initiative was dedicated to sustainable rural development with the aim to uplift families living below the poverty line. [12] In 1999, Lupin joined the Indian Pharmaceutical Alliance as a founding member. [13] [14]

In July 2015 the company announced its intention to acquire Gavis Pharmaceuticals and Novel Laboratories for $880 million. [15] [16]

The founder, Desh Bandhu Gupta died in June 2017 and was subsequently replaced as chairman by his wife, Manju Deshbandhu Gupta. [17]

In October 2019, Lupin announced the Appointment of Sreeji Gopinatham as Chief Information Officer (CIO). [18]

In March 2019, the US FDA put several Lupin drug plants on notice for quality problems, and indicated it might not approve future Lupin drug applications.

In May 2023, Lupin entered into an agreement to buy the French pharmaceutical company Medisol. [19]

Research and development

Lupin's research program covers the entire pharma product chain. The company's R&D program is headquartered in the Lupin Research Park located near Pune and Aurangabad that houses over 1,400 scientists. Lupin's R&D covers:

  • Process Research
  • Pharmaceutical Research

Businesses

Lupin's businesses encompass the entire pharmaceutical value chain, ranging from branded and generic formulations, APIs, advanced drug delivery systems to biotechnology. The company's drugs reach 70 countries [20] with a footprint that covers advanced markets such as USA, Europe, Japan, [21] Australia as well as emerging markets including India, the Philippines and South Africa to name a few. [22]

Key markets

United States

Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals Inc. (LPI), the company's US subsidiary is a $891 million enterprise. [23] It has a presence in the branded and generics markets of the US. In the branded business, Lupin operates in the CVS and Pediatric segments. The company is the market leader in 28 products out of the 77 products marketed in the US generics market, of which it is amongst the Top 3 by market share in 57 of these products (IMS Health, December 2014): Suprax (Cefixime), a paediatric antibiotic, is Lupin's top-selling product here. Other products in Lupin's branded portfolio include Antara< (Fenofibrate), Locoid lotion, Alinia (Nitazoxanide) and InspiraChambers (Anti-static valved holding chamber). The company is also the 5th largest and fastest growing generics player in the US (5.3% market share by prescriptions, IMS Health). Lupin's US brands business contributed 9% of total US sales whereas the generics business contributed 91% during FY 2014–15. [24]

India Region Formulations (IRF)

Lupin's IRF business focuses on Lifestyle diseases and Chronic disease therapy segments, particularly in Cardiology, Central Nervous System (CNS), Diabetology, Anti-Asthma, Anti-Infective, Gastro Intestinal and Oncology. The IRF business contributed 24% of the company's overall revenues for FY 2014–15, growing by 20% and recording revenues of ₹29,676 million (US$370 million) for FY 2014-15 as compared to ₹24,794 million (US$310 million) for FY 2013–14.

It has 12 manufacturing plants and 2 Research plants in India, as Jammu(J&K), Mandideep & Indore (Madhya pradesh), Ankaleswar & Dabasa (Gujarat), Tarapur, Aurangabad and Nagpur (Maharashtra), Goa, Visakhapatnam (Andhra Pradesh) and Sikkim; where research centre at Pune and Aurangabad. [25] Among these the baby plant is Nagpur plant which will the biggest formulation unit for Lupin in coming year.

Europe

Lupin's focus in the European Union encompasses Anti-Infectives, Cardiovascular, and CNS therapy areas, along with niche opportunities in segments like Oral Contraceptives, Dermatology and Ophthalmics. The company's presence in France is by way of a trade partnership; in Germany, it operates through its acquired entity Hormosan Pharma GmbH. ] (Hormosan); [26] while the UK business is a direct-to-market initiative.

Japan

Lupin is the fastest-growing Top 10 generic pharmaceuticals player in Japan (IMS) [ citation needed ]. It operates in Japan through its subsidiary, Kyowa Pharmaceutical Industry Co. Ltd. (Kyowa), a company acquired in 2007, [27] [28] and I’rom, Pharmaceutical Co. Ltd (IP), acquired in 2011. [29] [30] Kyowa has an active presence in Neurology, Cardiovascular, Gastroenterology and the Respiratory therapy segments. I'rom is a niche injectables company.

In 2014, Lupin entered into a strategic joint venture agreement with Toyama-based Japanese pharmaceuticals company, Yoshindo Inc. to create YL Biologics (YLB). [31] YLB will be jointly managed by both partners and will be responsible for conducting clinical development of certain biosimilars including regulatory fillings and obtaining marketing authorization in Japan.

In 2019, Lupin exited the generic pharmaceuticals business in Japan by divesting its stake in Kyowa to private equity firm Unison for an enterprise value of Japanese 57,361 million yen (Rs 3,702.4 crore). [32]

South Africa

Lupin's South African subsidiary, Pharma Dynamics (PD) [33] is the fastest growing and the 4th largest generic company in the South African market (IMS).[ citation needed ] The company is a market leader in the Cardiovascular segment and has a growing presence in Neurology, Gastroenterology and the Over the Counter (OTC) segments.

Australia

Lupin entered the Australian market through its subsidiary, Generic Health Pte. Ltd. (GH). [34] It subsequently acquired the worldwide marketing rights to the over-100-year-old Australian brand Goanna, [35] used for pain management.

Philippines

Lupin's Philippines subsidiary Multicare Pharmaceuticals (Multicare), [36] is a branded generic company focused on Women's Health, Pediatrics, Gastro-Intestinal and Diabetes care. FY 2012 also marked its foray into the Neurology segment when it entered into a strategic marketing partnership with Sanofi. [37]

Mexico & Latin America

In 2014, Lupin acquired 100% equity stake in Laboratories Grin, S.A. De C.V. (Grin), Mexico, a specialty pharmaceutical company engaged in the development, manufacturing and commercialization of branded ophthalmic products. This marked their entry into Mexico and the larger Latin American pharmaceuticals market. In May 2015, Lupin entered the Brazilian market with its acquisition of 100% stake in Medquímica Indústria Farmacêutica S.A., Brazil, (Medquímica). [38]

Key businesses

Anti-Tuberculosis

Lupin is a global leader in Cephalosporins, Cardiovasculars and the anti-TB space. The company is also a strategic supplier of anti-TB products to the Stop TB Partnership, with its formulations supplied to more than 50 countries through GDF procurement.

Rgwduen is also a global leader in anti-TB APIs, and is associated with the Revised National Tuberculosis Control Program of the Government of India. It supplies to various Government agencies, the Stop TB Partnership and various other international agencies like Pan American Health Organization (PAHO), Médecins Sans Frontières (MSF) and the Damien Foundation. Ethambutol, Rifampicin and Pyrazinamide are the company's top selling TB molecules.[ citation needed ]

Biotechnology research

The Lupin Biotechnology Research Group, based out of Ghotawade & Wakad, near Pune is focussed on developing biosimilars. As of May 2013, it has a pipeline of 10 biosimilar products under development, and is close to getting marketing authorization for 2 of its oncology products for the Indian market. Lupin has competencies for the complete development and manufacture of recombinant protein therapeutic products from high yielding and proprietary microbial and mammalian cell culture platforms. The Biotech R&D infrastructure offers product development capabilities ranging from clone development, process optimization, analytical method development, bioassay, formulation, stability studies, non-clinical and clinical studies backed by a sound understanding of regulatory and IP aspects. The company's biotech development programs are in compliance of and follow ICH, EMEA, and Indian Regulatory guidelines. Company has developed biosimilar versions of Etanercept, Filgrastim, Peg-filgrastim, Ranibizumab.

Diagnostics

Lupin forayed into diagnostics business in December 2021 to provide a comprehensive range of diagnostic tests in India which includes molecular diagnostics, cytogenetics, flow cytometry, microbiology and serology among others. [39] Lupin plans to enroll over 100 laboratories and 1'000 LupiMitra collection centres allover India between 2022 and 2025. 90% of the collection centres will be run by franchisees. [40]

Corporate social responsibility

The Lupin Human Welfare & Research Foundation (LHWRF) was set up in 1988. The project began with a set of rural development projects centred around 35 villages in Bharatpur District, Rajasthan. Later this expanded to other regions and states. The initiative has so far reached out to over 2.8 million people across over 3,400 villages in eight states of India including Rajasthan, Madhya Pradesh, Maharashtra, Uttarakhand, Gujarat and Goa. [12] In July 2018, Lupin foundation signed a statement of Intent with the National Institution for Transforming India (Niti Aayog), a policy think tank of the government of India, to collaborate in the Aspirational Districts Programme and support the development of three backward districts – Nandurbar in Maharashtra, Vidisha in Madhya Pradesh and Dholpur in Rajasthan. [41]

Related Research Articles

<span class="mw-page-title-main">Generic drug</span> Pharmaceutical equivalent to a brand-name product

A generic drug is a pharmaceutical drug that contains the same chemical substance as a drug that was originally protected by chemical patents. Generic drugs are allowed for sale after the patents on the original drugs expire. Because the active chemical substance is the same, the medical profile of generics is equivalent in performance compared to their performance at the time when they were patented drugs. A generic drug has the same active pharmaceutical ingredient (API) as the original, but it may differ in some characteristics such as the manufacturing process, formulation, excipients, color, taste, and packaging.

<span class="mw-page-title-main">Cipla</span> Indian multinational pharmaceutical company

Cipla Limited is an Indian multinational pharmaceutical company, headquartered in Mumbai. Cipla primarily develops medicines to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, and many other medical conditions.

<span class="mw-page-title-main">Meiji Seika Pharma</span> Japanese food and pharmaceutical company

Meiji Seika Pharma Co., Ltd., formerly Meiji Seika Kaisha, Ltd. is a Japanese pharmaceutical company. It is currently a subsidiary of Meiji Holdings and a Japanese leader in the area of infectious disease with 18% market share. It markets treatments for depression, obsessive-compulsive disorder, vaccines and allergy drugs. Meiji Pharma is doing research in generic anticancer drugs and biosimilars with partner organisations.

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology.

<span class="mw-page-title-main">Biocon</span> Indian multinational biopharmaceutical company

Biocon Limited is an Indian biopharmaceutical company based in Bangalore. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.

The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured in the world. Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.

<span class="mw-page-title-main">Actavis</span> Global pharmaceutical company

Actavis Generics is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial presence across approximately 100 countries. The company has global headquarters in Dublin, Ireland and administrative headquarters in Parsippany-Troy Hills, New Jersey, United States.

Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but gets a third of its revenue from the United States. Organon & Co. is an example of increasing women's representation on Wall Street with over 50% of its board of directors and executive leadership being female.

<span class="mw-page-title-main">Sun Pharma</span> Indian multinational pharmaceutical company

Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries across the globe. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world. The products cater to a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. Its active pharmaceutical products include baricitinib, brivaracetam, and dapaglifozin.

<span class="mw-page-title-main">Kyowa Kirin</span>

Kyowa Kirin Co., Ltd. is a Japanese pharmaceutical and biotechnology company under the Kirin Holdings, and is among the 40 largest in the world by revenue. The company is headquartered in Chiyoda-ku, Tokyo and is a member of the Nikkei 225 stock index.

<span class="mw-page-title-main">Glenmark Pharmaceuticals</span> Indian multinational pharmaceutical company

Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, India.

<span class="mw-page-title-main">Intas Pharmaceuticals</span> Indian multinational pharmaceutical company

Intas Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad. It is a producer of generic therapeutic drugs and engaged in contract clinical research and manufacturing. It has 18 manufacturing plants, 15 in India and the rest in United Kingdom and Mexico. In the financial year 2019, 69% of the company's revenue came from international markets while 31% came from India.

<span class="mw-page-title-main">Desh Bandhu Gupta</span> Indian billionaire, philanthropist, entrepreneur

Desh Bandhu Gupta was an Indian billionaire, philanthropist, entrepreneur and the founder of Lupin Limited, a multinational pharmaceutical company. At the time of his death, his net worth was estimated at US$3.6 billion.

<span class="mw-page-title-main">Aurobindo Pharma</span> Indian multinational pharmaceutical company

Aurobindo Pharma Limited is an Indian multinational pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad, India. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s area of activity includes six major therapeutic and product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. The company markets these products in over 125 countries. Its marketing partners include AstraZeneca and Pfizer.

Amneal Pharmaceuticals, Inc. is an American publicly traded generics and specialty pharmaceutical company. The company is headquartered in Bridgewater, New Jersey.

Biotechnology in India is a sunrise sector within the Indian economy. Agencies of the Government of India concerned with the biotechnology industry include the Department of Biotechnology and the proposed Biotechnology Regulatory Authority of India. As of 2022, the sector is valued at $80 billion. Biotechnology in India is in a growth phase and the sector is expected to be valued at $150 billion by 2025 and surpass $300 billion in value by 2030.

Alvogen is an Icelandic pharmaceuticals company founded in 2009. In 2014, a controlling stake in the company was acquired by CVC Capital Partners and Temasek Holdings. Alvogen has about 350 different medical and non-medical products, and both produces its own products and markets the products of brand name pharmaceutical companies.

Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.

<span class="mw-page-title-main">Laurus Labs</span> Indian pharmaceutical company

Laurus Labs is an Indian multinational pharmaceutical and biotechnology company headquartered in Hyderabad. Its focus areas include active pharmaceutical ingredients (APIs), generic formulations, custom synthesis (CDMO), biotechnology. veterinary APIs and agro chemicals. The company was founded in 2005 by Dr. Satyanarayana Chava.

Wilhelm Róbert Wessman is an Icelandic business executive and founder of the pharmaceutical and biotechnology companies Alvotech and Alvogen.

References

  1. ↑ "Welcome to Lupin World". Lupinworld.com. Archived from the original on 8 June 2012. Retrieved 30 May 2013.
  2. ↑ "Lupin goes all out to make up for lost chances - Corporate News". livemint.com. 8 February 2010. Retrieved 30 September 2010.
  3. ↑ "Welcome to Lupin World". Lupinworld.com. Archived from the original on 7 June 2013. Retrieved 30 May 2013.
  4. ↑ "Lupin outcome of board meeting". moneycontrol.com. 8 May 2013.
  5. ↑ "Lupin's Vinita Gupta, Nilesh Gupta win EY Entrepreneur Award 2015". 12 February 2016.
  6. ↑ "Board of Directors". Archived from the original on 7 October 2018. Retrieved 23 February 2016.
  7. 1 2 3 4 5 "Lupin Profit & Loss Statements".
  8. ↑ "Annual Report FY2021" (PDF). Lupin. Retrieved 17 May 2022.
  9. ↑ "Top five generic drug makers". europeanpharmaceuticalreview.com. Retrieved 22 May 2020.
  10. ↑ Megha Bahree. "Desh Bandhu Gupta". Forbes.
  11. ↑ "Guru of Generics- Business News". businesstoday.in. 26 May 2010. Retrieved 8 April 2019.
  12. 1 2 Bhatia, Navin (26 June 2017). "How Desh Bandhu Gupta Turned A Rs. 5000 Loan Into The Rs. 18,000 Crore Pharmaceutical Giant, Lupin". OfficeChai. Retrieved 8 April 2019.
  13. ↑ Dec 22, PTI (22 December 2022). "Indian pharma sector set for 'volume to value leadership' journey in 2023". The Economic Times. ISSN   0013-0389 . Retrieved 5 August 2023.
  14. ↑ "Introducing IPA- Indian Pharmaceutical Alliance". IPA, Indian Pharmaceutical Alliance. Retrieved 5 August 2023.
  15. ↑ Ketaki Gokhale (23 July 2015). "Lupin to Buy Gavis in $880 Million Deal to Expand in U.S." Bloomberg.com.
  16. ↑ "Lupin Acquires GAVIS Pharmaceuticals for $880M". 23 July 2015.
  17. ↑ PTI (11 August 2017). "Lupin appoints Manju Deshbandhu Gupta as chairman". Mint. Retrieved 8 April 2019.
  18. ↑ "Sreeji Gopinathan joins Lupin as Chief Information Officer". Medical Dialogues. 10 October 2019.
  19. ↑ MENAFN. "Lupin Announces Acquisition Of French Pharma Company Medisol". menafn.com. Retrieved 5 August 2023.
  20. ↑ "Lupin transforms into a global pharma company". timesofindia-economictimes. 30 April 2010.
  21. ↑ "Forbes India Magazine - The Japanese Are a Brand Conscious People, Says Lupin MD". forbesindia.com.
  22. ↑ "Know 10 largest Pharmaceutical Companies in India". Edu Dwar. Retrieved 28 July 2023.
  23. ↑ "Archived copy" (PDF). Archived from the original (PDF) on 17 October 2015. Retrieved 20 May 2015.{{cite web}}: CS1 maint: archived copy as title (link)
  24. ↑ "Lupin". lupinworld.com.
  25. ↑ "Lupin". lupinworld.com. Archived from the original on 25 February 2001. Retrieved 30 September 2010.
  26. ↑ "Lupin acquires Germany-based Hormosan Pharma". livemint.com. 30 July 2008.
  27. ↑ BS Reporter (11 October 2007). "Lupin buys Japan's Kyowa Pharma". business-standard.com.
  28. ↑ Watts, Himangshu (10 October 2007). "India's Lupin says acquires Japan's Kyowa Pharma". Reuters.
  29. ↑ "Lupin acquires Japan's I'rom Pharma". indianexpress.com. 17 November 2011.
  30. ↑ "Lupin to acquire Japan's I'rom Pharma". Firstpost. 17 November 2011.
  31. ↑ C. H. Unnikrishnan (23 April 2014). "Lupin, Yoshindo form JV for clinical development of biosimilars in Japan". livemint.com.
  32. ↑ "Lupin sells Japan arm to Unison for Rs 3,702 cr, exits generic business".
  33. ↑ "Lupin completes acquisition of Pharma Dynamics – The Financial Express". The Financial Express. 16 March 2015.
  34. ↑ Press Trust of India (29 September 2010). "Lupin acquires majority stake in Australian firm". business-standard.com.
  35. ↑ "Lupin acquires global rights for Australian brand Goanna". timesofindia-economictimes. 15 June 2011.
  36. ↑ "Pharma - Lupin buys Philippines drug firm Multicare". livemint.com. 26 March 2009.
  37. ↑ "Lupin, Sanofi-Aventis ink drug marketing pact in Philippines". livemint.com. 2 September 2011.
  38. ↑ "Lupin acquires Brazilian drug firm Medquimica". timesofindia-economictimes. 13 May 2015.
  39. ↑ "Lupin announces launch of its diagnostics business in India". The Financial Express. 11 December 2021. Retrieved 24 January 2022.
  40. ↑ Pilla, Viswanath (10 March 2022). "Lupin opens main reference lab in Kolkata for expansion in east India". Economic Times. Retrieved 28 July 2023.
  41. ↑ "Niti Aayog and Lupin foundation sign SoI". pib.nic.in (GOI press release).
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.